The law firm said it is examining whether Medline and certain officers or directors engaged in securities fraud after an FDA warning letter cited significant pharmaceutical manufacturing violations.
Pomerantz LLP said it is investigating claims on behalf of investors in Medline Industries, Inc. after a U.S. Food and Drug Administration warning letter cited significant violations of Current Good Manufacturing Practice regulations for finished pharmaceuticals. The firm said the probe is examining whether Medline and certain of its officers and/or directors engaged in securities fraud or other unlawful business practices. The warning letter, published June 2, 2026, said among other things that Medline failed to thoroughly investigate unexplained discrepancies or failures of a batch or its components to meet specifications. Medline shares fell $2.56, or 7.16%, to close at $33.19 on June 2, 2026.